New Analysis: No Surprises Act Cuts Out-Of-Network Emergency Spending by as Much as 52%

HaloMD’s analysis of No Surprises Act data estimates annual out-of-network emergency medicine savings of $978 million to $3.95 billion vs. a pre-NSA baseline of ~$641.71 per claim. OON emergency spending is modeled to have declined 13% to 52% since Jan-2022, with only ~9.5% of NSA-eligible OON claims proceeding to formal IDR in 2025. The mean 2025 IDR award is ~ $630 per claim, closely tracking the pre-NSA baseline, implying the savings largely come from initial payment/open negotiation rather than arbitration.

Analysis

The investable signal is not the savings estimate itself; it is the bargaining-power shift. If most eligible claims are settling outside formal IDR, out-of-network emergency medicine loses pricing optionality, which should slowly compress reimbursement for provider-heavy franchises while improving the predictability of medical cost trend for payors. That is a modest but real margin tailwind for UNH, CI, and ELV, with the benefit showing up first in renewal pricing and MLR rather than in an immediate EPS pop.

The second-order effect is consolidation pressure on smaller emergency medicine groups and hospital-based specialty platforms that relied on arbitration leverage. Scale players with broader contracting footprints can absorb lower unit economics better than independents, so this is structurally negative for fragmented provider models over 6-18 months. For hospitals, the effect is mixed: less out-of-network revenue is a headwind, but fewer billing disputes reduce administrative friction and legal expense; the net impact on large systems like HCA is likely smaller than the market fears.

The main contrarian risk is that this is a retrospective, vendor-produced analysis, so the exact dollar savings number is less important than whether CMS or the courts change the rules. If arbitration share re-accelerates, or if the next round of payer disclosures shows no MLR improvement, the thesis is diluted. Near term, the market may overtrade the headline and underappreciate that the real catalyst path is a 1-3 quarter reset in provider contracting rather than a day-one re-rating.

Key Decisions for Investors

• Long UNH/CI/ELV basket vs short THC on rallies over the next 2-4 weeks; thesis is that lower surprise-billing friction helps payer margins faster than it hurts diversified hospital operators. Cut if payer medical-cost ratios do not improve in the next reporting cycle or if CMS signals a provider-favorable rule change.
• Buy 2-3 month call spreads on UNH or CI on weakness rather than chasing common stock; the catalyst is gradual medical-cost trend improvement, not a single-quarter earnings beat. Risk/reward is better expressed with limited premium if the market is discounting the article as PR noise.
• Avoid initiating a direct long in any provider-heavy name that depends on out-of-network emergency pricing; if you want a public-market short expression, use THC as a cleaner proxy than HCA because the earnings quality is more sensitive to reimbursement mix. Use tight risk if HCA/THC guide to stable ED economics.
• Set a watch item on CMS IDR filings and any federal court rulings over the next 1-3 months; if IDR share stays below ~10% and awards remain anchored near QPA, maintain payer overweight. If arbitration volume inflects back above that band, unwind the thesis.